| Literature DB >> 25482335 |
Anna Burmester1, Bérengère Luthringer, Regine Willumeit, Frank Feyerabend.
Abstract
Magnesium-based implants exhibit various advantages such as biodegradability and potential for enhanced in vivo bone formation. However, the cellular mechanisms behind this possible osteoconductivity remain unclear. To determine whether high local magnesium concentrations can be osteoconductive and exclude other environmental factors that occur during the degradation of magnesium implants, magnesium salt (MgCl2) was used as a model system. Because cell lines are preferred targets in studies of non-degradable implant materials, we performed a comparative study of 3 osteosarcoma-derived cell lines (MG63, SaoS2 and U2OS) with primary human osteoblasts. The correlation among cell count, viability, cell size and several MgCl2 concentrations was used to examine the influence of magnesium on proliferation in vitro. Moreover, bone metabolism alterations during proliferation were investigated by analyzing the expression of genes involved in osteogenesis. It was observed that for all cell types, the cell count decreases at concentrations above 10 mM MgCl2. However, detailed analysis showed that MgCl2 has a relevant but very diverse influence on proliferation and bone metabolism, depending on the cell type. Only for primary cells was a clear stimulating effect observed. Therefore, reliable results demonstrating the osteoconductivity of magnesium implants can only be achieved with primary osteoblasts.Entities:
Keywords: ALP, Alkaline phosphatase; BSP, Bone sialoprotein; Cbfa1, Runt-related transcription factor 2; Col, Collagen; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; HPSE, Heparanase; MG63; OB, osteoblasts; OC, Osteocalcin; OPG, Osteoprotegerin; OPN, Osteopontin; PCR, Polymerase chain reaction; RANKL, Receptor Activator of NF-κB Ligand; SaoS2; U2OS; gene expression; magnesium; osteoblasts
Mesh:
Substances:
Year: 2014 PMID: 25482335 PMCID: PMC4578555 DOI: 10.4161/21592527.2014.967616
Source DB: PubMed Journal: Biomatter ISSN: 2159-2527
Figure 1.Media osmolality. Osmolality due to increased MgCl2 concentrations in media used in this study. DMEM GlutaMAX I is indicated by diamonds, DMEM is indicated by squares and McCoy's 5A is indicated by triangles.
Figure 2.Cell proliferation. Cell count (A), viability (B) and division and proliferation rate (C) of the osteosarcoma derived cell lines U2OS, MG63 and SaoS2 and osteoblasts (OB) after incubation with increasing concentrations of MgCl2 (0-25 mM). Significant differences between control and indicated conditions are presented by asterisks or hash marks (P < 0.05 = *, P < 0.001 = #). The viability is normalized to the total amount of cells measured in (A).
Figure 3.Cell size of trypsinised cells in suspension (A) and adherent cells on fibronectin coated glass slides (B) of the osteosarcoma derived cell lines U2OS, MG63 and SaoS2 and osteoblasts (OB) after incubation with increasing extracellular MgCl2 concentrations (0-25 mM). Significant differences between the control and indicated conditions are presented by asterisks or hash marks (P < 0.05 = *, P < 0.001 = #).
Figure 4.Cell size of adherent cells on fibronectin coated glass slides. Fluorescent microscopy of U2OS cells under cell culture conditions (A) and after addition of 25 mM MgCl2 (B), MG63 (C and D), SaoS2 (E and F) and osteoblasts (G and H), respectively. Actin filaments were stained green, and the nuclei were stained blue. The scales show a length of 50 μm, except the scale in H, where the length is 100 μm.
Figure 5.Qualitative gene expression. Comparison of gene expression of various genes involved in bone formation from human osteoblasts (OB) and osteosarcoma cell lines MG63, SaoS2 and U2OS under cell culture conditions (A) and after incubation with 25 mM MgCl2 (B). The sizes of the DNA ladder are indicated in (C). GAPDH: glyceraldehyde 3-phosphate dehydrogenase; HPSE: Heparanase; ALP: alkalinephosphatase; RANKL: RANK ligand; BSP: bone sialoprotein; Cbfa1: runt-related transcription factor 2; OC: osteocalcin, OPN: osteopontin; OPG: osteoprotegerin; Col: Collagen.
Change in relative density (% of control)
| U2OS | MG63 | SaoS2 | osteoblasts | |
|---|---|---|---|---|
| GAPDH | 100 | 100 | 100 | 100 |
| HPSE | 169.71 | 111.45 | 140.14 | 82.56 |
| ALP | 69.87 | 29.63 | 127.97 | 152.46 |
| RANKL | 304.56 | 0.01 | 89.23 | 108.45 |
| BSP | 0.011 | 49.93 | 115.67 | 55.29 |
| Cbfa1 | 957.25 | 29.17 | 139.36 | 111.50 |
| OC | 0.015 | 0.019 | 0.01 | 87.63 |
| OPN | 33.32 | 37.64 | 0.02 | 84.23 |
| OPG | 210.18 | 46.22 | 128.98 | 29.27 |
| Col 1 | 169.71 | 111.45 | 101.19 | 98.92 |
| Col 10 | 69.87 | 29.63 | 140.14 | 92.15 |
Figure 6.Semi-quantitative gene expression. Gene expression of genes involved in bone metabolism from osteosarcoma-derived cell lines U2OS (A), MG63 (B), SaoS2 (C) and osteoblasts (D) after incubation with various MgCl2 concentrations (0-25 mM). Gene expression was normalized to the expression of GAPDH and ß-Actin. Expression of 0 mM MgCl2 was set as the control (= 1). GAPDH: glyceraldehyde 3-phosphate dehydrogenase; ALP: alkaline phosphatase; BSP: bone sialoprotein; OPN: osteopontin; OPG: osteoprotegerin; RANKL: RANK ligand. Significant differences between the control and indicated conditions are presented by asterisks or hash marks (P < 0.05 = *, P < 0.001 = #).
Osteoprotegerin/RANK ligand gene expression ratios examined by qPCR
| U2OS | MG63 | SaoS2 | osteoblasts | |
|---|---|---|---|---|
| 5 mM MgCl2 | 1.5 | 0.8 | 1.4 | 0.7 |
| 10 mM MgCl2 | 0.7 | 2.0 | 1.8 | 0.2 |
| 15 mM MgCl2 | 0.8 | 2.3 | 1.6 | 2.2 |
| 20 mM MgCl2 | 1.0 | 1.2 | 1.8 | 0.6 |
| 25 mM MgCl2 | 3.1 | 1.7 | 1.3 | 0.5 |
Reverse transcription-PCR (RT-PCR) primer sequences
| Gene | abbreviation | RT-PCR-Primer (5’-3’) | Ta [°C] | product size |
|---|---|---|---|---|
| Glyceraldehyde 3-phosphate dehydrogenase | GAPDH | ACCACAGTCCATGCCATCAC | 55 | 452 |
| TTCACCACCCTGTTGCTGTA | ||||
| Heparanase | HPSE | TGGACCTGGACTTCTTCACC | 53 | 216 |
| TTGATTCCTTCTTGGGATCG | ||||
| Alkaline phosphatase | ALP | ACGTGGCTAAGAATGTCATC | 53 | 475 |
| CTGGTAGGCGATGTCCTTA | ||||
| Receptor Activator of NF-κB Ligand | RANKL | CAGGAGACCTAGCTACAGA | 49 | 418 |
| CAAGGTCAAGAGCATGGA | ||||
| Bone sialoprotein | BSP | AAGCAATCACCAAAATGAAGACT | 55 | 188 |
| TGGAAATCGTTTTAAATGAGGATA | ||||
| Runt-related transcription factor 2 | Cbfa1 | CCCCACGACAACCGCACC | 55 | 289 |
| CACTCCGGCCCACAAATCTC | ||||
| Osteocalcin | OC | CATGAGAGCCCTCACA | 48 | 315 |
| AGAGCGACACCCTAGAC | ||||
| Osteopontin | OPN | CCAAGTAAGTCCAACGAAAG | 55 | 347 |
| GGTGATGTCCTCGTCTGTA | ||||
| Osteoprotegerin | OPG | AGACTTTCCAGCTGCTGA | 49 | 469 |
| GGATCTCGCCAATTGTGA | ||||
| Collagen type 1 | Col1 | AAAGGCAATGCTCAAACACC | 49 | 159 |
| TCAAAAACGAAGGGGAGATG | ||||
| Collagen type 2 | Col2 | GTGGAGCAGCAAGAGCAAGGA | 61 | 334 |
| CTTGCCCCACTTACCAGTGTG | ||||
| Collagen type 10 | Col10 | TCCAAAAGGTGATCCTGGAG | 55 | 181 |
| CCCTTTAGACCCAGGGAATC |
Quantitative real-time PCR (qPCR) primer sequences
| Gene | abbreviation | qPCR-Primer (5’-3’) | product size |
|---|---|---|---|
| ß-Actin | ß-Actin | CTTCCTGGGCATGGAGTC | 134 |
| TGATCTTCATTGTGCTGGGT | |||
| Glyceraldehyde 3-phosphate dehydrogenase | GAPDH | GTCGGAGTCAACGGATTTG | 143 |
| TGGGTGGAATCATATTGGAA | |||
| alkaline phosphatase | ALP | CACCCACGTCGATTGCATCT | 211 |
| TAGCCACGTTGGTGTTGAGC | |||
| Bone sialoprotein | BSP | TGGATGAAAACGAACAAGGCA | 200 |
| AAACCCACCATTTGGAGAGGT | |||
| Osteocalcin | OC | GGCAGCGAGGTAGTGAAGAG CTGGAGAGGAGCAGAACTGG | 230 |
| Osteopontin | OPN | CTCCATTGACTCGAACGACTC | 230 |
| CAGGTCTGCGAAACTTCTTAGAT | |||
| Osteoprotegerin | OPG | CGCTCGTGTTTCTGGACAT | 112 |
| GGACATTTGTCACACAACAGC | |||
| Receptor Activator of NF-κB Ligand | RANKL | ATACCCTGATGAAAGGAGGA | 202 |
| GGGGCTCAATCTATATCTCG |